Cost–benefit analysis of enhancing the uptake of long-acting reversible contraception in Australia
Kristine Concepcion A , Sarina Lacey B , Kevin McGeechan A C , Jane Estoesta A , Deborah Bateson A and Jessica Botfield A D
+ Author Affiliations
- Author Affiliations
A Family Planning NSW, 328–336 Liverpool Road, Ashfield, NSW 2131, Australia. Email: kris.alba@gmail.com; kevinm@fpnsw.org.au; janee@fpnsw.org.au; deborahb@fpnsw.org.au
B The Centre for International Economics, Level 7, 8 Spring Street, Sydney, NSW 2000, Australia. Email: slacey@thecie.com.au
C School of Public Health, The University of Sydney, Edward Ford Building (A27), Fisher Road, Sydney, NSW 2006, Australia.
D Corresponding author. Email: jessicab@fpnsw.org.au
Australian Health Review 44(3) 385-391 https://doi.org/10.1071/AH18190
Submitted: 20 September 2018 Accepted: 8 July 2019 Published: 28 October 2019
Abstract
Objective Long-acting reversible contraception (LARC) is the most effective form of reversible contraception, but its use in Australia is low compared with other countries. The aim of this study was to evaluate the economic effect of an increase in LARC uptake to international rates.
Methods An economic model was designed to assess two scenarios, namely increasing the current rate of LARC uptake of 12.5% to the international benchmark of 14.8% among: (1) women currently using the oral contraceptive pill (OCP); and (2) women at risk of pregnancy and not using contraception. Model inputs included cost of contraceptive methods, discontinuation rates and abortion and miscarriage costs associated with unintended pregnancies.
Results Women who switch from an OCP to LARC would save A$114–157 per year. Those not currently using any contraception who adopt LARC would incur costs of A$36–194 per year, but would reap savings from the reduction in unintended pregnancies. Over 5 years there would be a net saving of A$74.4 million for Scenario 1 and A$2.4 million for Scenario 2.
Conclusion Greater use of LARC would result in a net gain in economic benefits to Australia. These benefits are largely driven by women switching from an OCP to LARC who have reduced costs, as well as women wishing to avoid pregnancy who choose to use LARC rather than no method. This evidence will support women making an informed contraceptive choice and policy makers in increasing the accessibility of LARC.
What is known about the topic? LARC is the most effective form of reversible contraception, but uptake in Australia is relatively low.
What does this paper add? There are economic benefits to society for women who switch from an OCP to LARC, as well as for women who switch from no contraception to LARC.
What are the implications for practitioners? The findings of this study will support women in making an informed contraceptive choice and policy makers in increasing the accessibility of LARC.
Additional keywords: economics, LARC, pregnancy, reproductive health.
References
[1] Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, Secura GM. Effectiveness of long-acting reversible contraception. N Engl J Med 2012; 366 1998–2007.| Effectiveness of long-acting reversible contraception.Crossref | GoogleScholarGoogle Scholar | 22621627PubMed |
[2] Sundaram A, Vaughan B, Kost K, Bankole A, Finer LB, Susheela S, Trussell J. Contraceptive failure in the United States: estimates from the 2006–2010 National Survey of Family Growth. Perspect Sex Reprod Health 2017; 49 7–16.
| Contraceptive failure in the United States: estimates from the 2006–2010 National Survey of Family Growth.Crossref | GoogleScholarGoogle Scholar | 28245088PubMed |
[3] Family Planning New South Wales, Family Planning Victoria, True Relationships and Reproductive Health. Contraception: an Australian clinical practice handbook. Sydney: Family Planning NSW; 2016.
[4] Richters J, Fitzadam S, Yeung A, Caruana T, Rissel C, Simpson JM, deVisser RO. Contraceptive practices among women: the Second Australian Study of Health and Relationships. Contraception 2016; 5 548–55.
| Contraceptive practices among women: the Second Australian Study of Health and Relationships.Crossref | GoogleScholarGoogle Scholar |
[5] United Nations, Department of Economic and Social Affairs Population Division. Trends in contraceptive use worldwide 2015. New York: United Nations; 2015. Available at: https://www.un.org/en/development/desa/population/publications/pdf/family/trendsContraceptiveUse2015Report.pdf [verified 1 October 2019]
[6] Mazza D, Bateson D, Frearson M, Goldstone P, Kovacs G, Baber R. Current barriers and potential strategies to increase the use of long-acting reversible contraception (LARC) to reduce the rate of unintended pregnancies in Australia: an expert roundtable discussion. Aust N Z J Obstet Gynaecol 2017; 57 206–12.
| Current barriers and potential strategies to increase the use of long-acting reversible contraception (LARC) to reduce the rate of unintended pregnancies in Australia: an expert roundtable discussion.Crossref | GoogleScholarGoogle Scholar | 28294293PubMed |
[7] Secura GM, Allsworth JE, Madden T, Mullersman JL, Peipert JF. The contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception. Am J Obstet Gynecol 2010; 203 115.e1–e7.
| The contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception.Crossref | GoogleScholarGoogle Scholar |
[8] Henry N, Schlueter M, Lowin J, Lekander I, Filonenko A, Trussell J, Skjeldestad FE. Cost of unintended pregnancy in Norway: a role for long-acting reversible contraception. J Fam Plann Reprod Health Care 2015; 41 109–15.
| Cost of unintended pregnancy in Norway: a role for long-acting reversible contraception.Crossref | GoogleScholarGoogle Scholar | 25537792PubMed |
[9] Mavranezouli I, Group LGD. The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline. Hum Reprod 2008; 23 1338–45.
| The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline.Crossref | GoogleScholarGoogle Scholar | 18372257PubMed |
[10] Trussell J, Henry N, Hassan F, Prezioso A, Law A, Filonenko A. Burden of unintended pregnancy in the United States: potential savings with increased use of long-acting reversible contraception. Contraception 2013; 87 154–61.
| Burden of unintended pregnancy in the United States: potential savings with increased use of long-acting reversible contraception.Crossref | GoogleScholarGoogle Scholar | 22959904PubMed |
[11] Trussell J, Hassan F, Henry N, Pocoski J, Law A, Filonenko A. Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg in contraception. Contraception 2014; 89 451–9.
| Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg in contraception.Crossref | GoogleScholarGoogle Scholar | 24576791PubMed |
[12] Trussell J, Lalla AM, Doan QV, Reyes E, Pinto L, Gricar J. Cost effectiveness of contraceptives in the United States. Contraception 2009; 79 5–14.
| Cost effectiveness of contraceptives in the United States.Crossref | GoogleScholarGoogle Scholar | 19041435PubMed |
[13] Chiou CF, Trussell J, Reyes E, Knight K, Wallace J, Udani J, Oda K, Borenstein J. Economic analysis of contraceptives for women. Contraception 2003; 68 3–10.
| Economic analysis of contraceptives for women.Crossref | GoogleScholarGoogle Scholar | 12878280PubMed |
[14] Phillips CJ. Economic analysis of long-term reversible contraceptives. Focus on Implanon. Pharmacoeconomics 2000; 17 209–21.
| Economic analysis of long-term reversible contraceptives. Focus on Implanon.Crossref | GoogleScholarGoogle Scholar | 10947343PubMed |
[15] Sonnenberg FA, Burkman RT, Hagerty CG, Speroff L, Speroff T. Costs and net health effects of contraceptive methods. Contraception 2004; 69 447–59.
| Costs and net health effects of contraceptive methods.Crossref | GoogleScholarGoogle Scholar | 15157789PubMed |
[16] Richters J, Fitzadam S, Yeung A, Caruana T, Rissel C, Simpson JM, deVisser RO. Contraceptive practices among women: the Second Australian Study of Health and Relationships. Contraception 2016; 94 548–55.
| Contraceptive practices among women: the Second Australian Study of Health and Relationships.Crossref | GoogleScholarGoogle Scholar | 27373543PubMed |
[17] Livsey A. How much do abortions cost across Australia? – explainer. 2017. Available at: https://www.theguardian.com/news/datablog/2017/aug/22/how-much-do-abortions-cost-across-australia-explainer [verified 3 October 2019].
[18] Goldstone P, Michelson J, Williamson E. Early medical abortion using low-dose mifepristone followed by buccal misoprostol: a large Australian observational study. Med J Aust 2012; 197 282–286.
| Early medical abortion using low-dose mifepristone followed by buccal misoprostol: a large Australian observational study.Crossref | GoogleScholarGoogle Scholar | 22938126PubMed |
[19] Hall JA, Benton L, Copas A, Stephenson J. Pregnancy intention and pregnancy outcome: systematic review and meta-analysis. Matern Child Health J 2017; 21 670–704.
| Pregnancy intention and pregnancy outcome: systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar | 28093686PubMed |
[20] Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, Secura G. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011; 117 1105–13.
| Continuation and satisfaction of reversible contraception.Crossref | GoogleScholarGoogle Scholar | 21508749PubMed |
[21] Weisberg E, Bateson D, McGeechan K, Mohapatra L. A three-year comparative study of continuation rates, bleeding patterns and satisfaction in Australian women using a subdermal contraceptive implant or progestogen releasing-intrauterine system. Eur J Contracept Reprod Health Care 2014; 19 5–14.
| A three-year comparative study of continuation rates, bleeding patterns and satisfaction in Australian women using a subdermal contraceptive implant or progestogen releasing-intrauterine system.Crossref | GoogleScholarGoogle Scholar | 24229367PubMed |
[22] Griffiths EK, Marley JV, Friello D, Atkinson DN. Uptake of long-acting, reversible contraception in three remote Aboriginal communities: a population-based study. Med J Aust 2016; 205 21–5.
| Uptake of long-acting, reversible contraception in three remote Aboriginal communities: a population-based study.Crossref | GoogleScholarGoogle Scholar | 27362683PubMed |
[23] Weisberg E, Hickey M, Palmer D, O’Connor V, Salamonsen LA, Findlay JK, Fraser IS. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod 2006; 21 295–302.
| A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon.Crossref | GoogleScholarGoogle Scholar | 16284061PubMed |
[24] Agrawal A, Robinson C. An assessment of the first 3 years’ use of Implanon in Luton. J Fam Plann Reprod Health Care 2005; 31 310–12.
| An assessment of the first 3 years’ use of Implanon in Luton.Crossref | GoogleScholarGoogle Scholar | 16274557PubMed |
[25] Lakha F, Glasier AF. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting. Contraception 2006; 74 287–9.
| Continuation rates of Implanon in the UK: data from an observational study in a clinical setting.Crossref | GoogleScholarGoogle Scholar | 16982226PubMed |
[26] Arribas-Mir L, Rueda-Lozano D, Agrela-Cardona M, Cedeno-Benavides T, Olvera-Porcel C, Bueno-Cavanillas A. Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain. Contraception 2009; 80 457–62.
| Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain.Crossref | GoogleScholarGoogle Scholar | 19835720PubMed |
[27] Diaz J, Bahamondes L, Monteiro I, Petta C, Hildalgo MM, Arce XE. Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brazil. Contraception 2000; 62 59–61.
| Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brazil.Crossref | GoogleScholarGoogle Scholar | 11102588PubMed |
[28] Lipetz C, Phillips C, Fleming C. Actual cost of providing long-acting reversible contraception: a study of Implanon cost. J Fam Plann Reprod Health Care 2009; 35 75–9.
| Actual cost of providing long-acting reversible contraception: a study of Implanon cost.Crossref | GoogleScholarGoogle Scholar | 19356275PubMed |
[29] O’Neil-Callahan M, Peipert JF, Zhao Q, Madden T, Secura G. Twenty-four-month continuation of reversible contraception. Obstet Gynecol 2013; 122 1083–91.
| Twenty-four-month continuation of reversible contraception.Crossref | GoogleScholarGoogle Scholar | 24104781PubMed |
[30] Taft AJ, Shankar M, Black KI, Mazza D, Hussainy S, Lucke JC. Unintended and unwanted pregnancy in Australia: a cross-sectional, national random telephone survey of prevalence and outcomes. Med J Aust 2018; 209 407–8.
| Unintended and unwanted pregnancy in Australia: a cross-sectional, national random telephone survey of prevalence and outcomes.Crossref | GoogleScholarGoogle Scholar | 30282564PubMed |
[31] Black AY, Guilbert E, Hassan F, Chatziheofilou I, Lowin J, Jeddi M, Filonenko A, Trussell J. The cost of unintended pregnancies in Canada: estimating direct cost, role of imperfect adherence, and the potential impact of increased use of long-acting reversible contraceptives. J Obstet Gynaecol Can 2015; 37 1086–97.
| The cost of unintended pregnancies in Canada: estimating direct cost, role of imperfect adherence, and the potential impact of increased use of long-acting reversible contraceptives.Crossref | GoogleScholarGoogle Scholar | 26637081PubMed |
[32] Bateson DJ, Black KI, Sawleshwarkar S. The Guttmacher–Lancet Commission on sexual and reproductive health and rights: how does Australia measure up? Med J Aust 2019; 210 250–2.e1.
| The Guttmacher–Lancet Commission on sexual and reproductive health and rights: how does Australia measure up?Crossref | GoogleScholarGoogle Scholar | 30861126PubMed |
[33] Kemeny F, Digiusto E, Bateson D. Insertion of intrauterine contraceptive devices by registered nurses in Australia. Aust N Z J Obstet Gynaecol 2016; 56 92–6.
| Insertion of intrauterine contraceptive devices by registered nurses in Australia.Crossref | GoogleScholarGoogle Scholar | 26662068PubMed |
[34] Temple-Smith M, Sanci L. LARCs as first-line contraception: what can general practitioners advise young women? Aust Fam Physician 2017; 46 710–5.
| 29036768PubMed |
[35] Diedrich JT, Desai S, Zhao Q, Secura G, Madden T, Peipert JF. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol 2015; 212 50.e1–e8.
| Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction.Crossref | GoogleScholarGoogle Scholar |
